1. VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo;Muhlhauser;Circ Res,1995
2. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer;Amaya;Cancer Lett,1997
3. Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers;Nakata;Int J Cancer,1998
4. Giantonio BJ, Catalano PJ, Meropol NJ et al. The addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer (adv CRC): an updated interim analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. In: Proceedings of the 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract #241.
5. Hurwitz H, Fehrenbacher L, Hainsworth J, et al. Bevacizumab in combination with 5-flourouracil and leucovorin: a promising regimen for first-line metastatic colorectal cancer. In: Proceedings of the 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract #286.